Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Nathalie Bardy-Bouxin"'
Autor:
Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Rocco Crescenzo, Nathalie Bardy-Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, Liza DeAnnuntis, Tim H. Brümmendorf, H. Jean Khoury
Publikováno v:
Haematologica, Vol 103, Iss 8 (2018)
Bosutinib is a Src/Abl tyrosine kinase inhibitor indicated for adults with newly-diagnosed Philadelphia positive chronic myeloid leukemia or with resistant/intolerant disease. We report the final results of a phase I/II study of second-line bosutinib
Externí odkaz:
https://doaj.org/article/f02bf4a3d3a344c189bcc6eb920d80f3
Autor:
Wells A. Messersmith, Charles Zacharchuk, Kathleen Turnbull, Eric Leip, Poe-Hirr Hsyu, Nathalie Bardy-Bouxin, Shefali Agarwal, Richat Abbas, Gregory M. Springett, Elena G. Chiorean, Philip J. Gold, Mitesh J. Borad, Barbara J. Gitlitz, Mansoor N. Saleh, Smitha S. Krishnamurthi, Adil I. Daud
PDF file - 89K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4587c6678ceb7f5636d4a877514e37
https://doi.org/10.1158/1078-0432.22444170
https://doi.org/10.1158/1078-0432.22444170
Autor:
Andrea Viqueira, Henrik Hjorth-Hansen, T H Brümmendorf, Gail J. Roboz, Nathalie Bardy-Bouxin, J.L. Steegmann, Francis J. Giles, J. E. Cortes, Philippe Rousselot, C. Gambacorti-Passerini, J.M. Leone, A. Hochhaus, Eric Leip, P. Le Coutre, Leif Stenke, Francisco Cervantes
Publikováno v:
HemaSphere. 3:160-161
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a647693b74488d7b183eb9ae5c8e3e8
https://doi.org/10.1097/01.hs9.0000559872.98250.4c
https://doi.org/10.1097/01.hs9.0000559872.98250.4c
Autor:
Tim H. Brümmendorf, Kathleen Turnbull, Eric Leip, Ewa Matczak, Hanna Jean Khoury, Nathalie Bardy-Bouxin, Mark Shapiro, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, Anna G. Turkina
Publikováno v:
American Journal of Hematology
Long‐term efficacy and safety of bosutinib (≥4 years follow‐up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cea9bb858c175026ab1fdcedfe8d3827
https://doi.org/10.1002/ajh.24034
https://doi.org/10.1002/ajh.24034
Autor:
Michael W. Deininger, Allison Jeynes-Ellis, Carlo Gambacorti-Passerini, Valentín García-Gutiérrez, Jorge E. Cortes, Dragana Milojkovic, Laurence Reilly, Charles Chuah, Tim H. Brümmendorf, Nathalie Bardy-Bouxin, Dong-Wook Kim, Nataliia Glushko, Irina Dyagil, Andreas Hochhaus, P. le Coutre, Michael J. Mauro, Eric Leip
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Journal of Clinical Oncology
Consejería de Sanidad de la Comunidad de Madrid
Journal of Clinical Oncology
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy and safety of bosutinib ver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f315d5f9352b405a750e87a0362bdb1
https://pubmed.ncbi.nlm.nih.gov/29206554
https://pubmed.ncbi.nlm.nih.gov/29206554
Autor:
Philippe Schafhausen, Kay Noonan, H. Jean Khoury, Tim H. Brümmendorf, Jeffrey H. Lipton, Rocco J. Crescenzo, Carlo Gambacorti-Passerini, Liza DeAnnuntis, Mark Shapiro, Nathalie Bardy-Bouxin, Eric Leip, Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim
Publikováno v:
Haematologica
Haematologica 103(8), 1298-1307 (2018). doi:10.3324/haematol.2017.171249
Haematologica 103(8), 1298-1307 (2018). doi:10.3324/haematol.2017.171249
Bosutinib is a Src/Abl tyrosine kinase inhibitor indicated for adults with newly-diagnosed Philadelphia positive chronic myeloid leukemia or with resistant/intolerant disease. We report the final results of a phase I/II study of second-line bosutinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061ed85905bd6fecfc96f40a738c4cf1
https://pubmed.ncbi.nlm.nih.gov/29773593
https://pubmed.ncbi.nlm.nih.gov/29773593
Autor:
Justin M. Watts, Camille N. Abboud, B. Douglas Smith, Jocelyn M Leone, Andreas Hochhaus, Gianantonio Rosti, Frank Giles, Susanne Saussele, Ulla Strömberg, Bjørn Tore Gjertsen, Andrea Viqueira, Carlo Gambacorti-Passerini, Pilar Giraldo-Castellano, Nathalie Bardy-Bouxin, Tim H. Brümmendorf, Eric Leip
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S290
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bba9a45a8252646d2ac01585e2edaa6e
https://doi.org/10.1016/j.clml.2019.07.235
https://doi.org/10.1016/j.clml.2019.07.235
Autor:
Elena G. Chiorean, Barbara J. Gitlitz, Mitesh J. Borad, Nathalie Bardy-Bouxin, Wells A. Messersmith, Richat Abbas, Charles Zacharchuk, Kathleen Turnbull, Philip J. Gold, Adil Daud, Poe-Hirr Hsyu, Gregory M. Springett, Smitha S. Krishnamurthi, Shefali Agarwal, Mansoor N. Saleh, Eric Leip
Publikováno v:
Clinical Cancer Research. 18:1092-1100
Purpose: Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial in patients with advanced solid tumor malignancies. Patients and Methods: This trial was conducted in 2 part
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b739b676b1699f8aa13ab1b35c6645
https://doi.org/10.1158/1078-0432.ccr-11-2378
https://doi.org/10.1158/1078-0432.ccr-11-2378
Autor:
Iryna Dyagil, Michael J. Mauro, Valentín García Gutiérrez, Michael W. Deininger, Dragana Milojkovic, Rocco J. Crescenzo, Nathalie Bardy-Bouxin, Jorge E. Cortes, Eric Leip, Philipp le Coutre, Carlo Gambacorti-Passerini, T H Brümmendorf, Dong-Wook Kim, A. Hochhaus, Charles Chuah, Natalia Glushko
Publikováno v:
Blood. 130:896-896
Introduction: Bosutinib is a potent SRC/ABL tyrosine kinase inhibitor approved for treatment of adults with CML resistant or intolerant to prior therapy. Here we compare the efficacy and safety of first-line bosutinib versus imatinib in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::341fe42af5353a58051f528d7fa12095
https://doi.org/10.1182/blood.v130.suppl_1.896.896
https://doi.org/10.1182/blood.v130.suppl_1.896.896
Publikováno v:
Biologics : Targets & Therapy
Dear editor Miller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), yet by the omission of an approved agent within the same class of drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1cd3efbe69156f89a610da4f037d124
https://pubmed.ncbi.nlm.nih.gov/25733805
https://pubmed.ncbi.nlm.nih.gov/25733805